Background: Piperine is a great lead compound, as a phytopharmaceutical with reported neuroprotective effects in neurodegenerative diseases. HJ105, a piperine derivative with high affinity to Keap1 receptor, attracts increasing attention in Alzheimer's disease (AD) treatment.
Purpose: This work mainly aimed to study HJ105's therapeutic effects on Aβ-associated AD and the underpinning mechanisms.